Clinical Trials Sponsored by National Cancer Institute (NCI)

Total 22256 results

National Cancer Center, Korea

Unknown

Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Lung Cancer

Korea, Republic of
National Cancer Center, Korea

Unknown

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer
Institut Bergonié

Completed

Effect of Advertisements on Treatment Compliance in Women With Breast Cancer

Breast Cancer
Institut Curie

Completed

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

France
Institut Bergonié

Completed

MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer

Breast Cancer

France
Institut Bergonié

Completed

Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer

Pain | Breast Cancer | Psychosocial Effects of Cancer and Its Treatment
Institut Curie

Unknown

Study of Tumor and Blood Samples From Women With Breast Cancer

Breast Cancer

France
Institut Bergonié

Unknown

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

France
Institut Curie

Unknown

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

Breast Cancer | Metastatic Cancer

France
National Eye Institute (NEI)
National Cancer Institute (NCI)

Recruiting

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Stargardt-Like Macular Dystrophy

United States
Institut Curie

Completed

Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer

Breast Cancer

France
Institut Curie

Completed

Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma

Intraocular Melanoma
Barrett Cancer Center
National Cancer Institute (NCI)

Unknown

Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain

Brain and Central Nervous System Tumors | Radiation Toxicity | Cognitive/Functional Effects

United States
Barrett Cancer Center

Completed

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

Brain and Central Nervous System Tumors

United States
Aichi Cancer Center

Unknown

Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer

Head and Neck Cancer

Japan
Institut Curie

Unknown

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Intraocular Melanoma

France
Barrett Cancer Center

Unknown

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

Brain and Central Nervous System Tumors

United States
Barrett Cancer Center

Unknown

Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Aichi Cancer Center

Completed

Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx

Head and Neck Cancer

Japan
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)

Not yet recruiting

Studying TAK-243 in Patients With Advanced Cancer

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)

Not yet recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, China
National Cancer Institute (NCI)

Not yet recruiting

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recurrent Salivary Gland Carcinoma | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma | Locally Advanced Salivary Gland Carcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing ONC201 to Prevent Colorectal Cancer

Familial Adenomatous Polyposis | Colorectal Carcinoma | Colorectal Adenomatous Polyp | Multiple Adenomatous Polyps

United States
National Cancer Institute (NCI)

Not yet recruiting

MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study

Acute Myeloid Leukemia | Myelodysplastic Syndrome
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Malignant Solid Neoplasm | Breast Carcinoma | NUT Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
National Cancer Institute (NCI)

Recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
National Cancer Institute (NCI)

Recruiting

GCC Agonist Signal in the Small Intestine

Gastroesophageal Reflux Disease | Barrett Esophagus | Malignant Digestive System Neoplasm

United States

Clinical Trials Sponsored by National Cancer Institute (NCI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations